In a 16-to-2 vote, the FDA Antimicrobial Drugs Advisory Committee (AMDAC) recommended approval of a new indication for emtricitabine–tenofovir alafenamide (F/TAF; Descovy, Gilead) for pre-exposure prophylaxis (PrEP) to reduce the risk for HIV in some, but not all, at-risk populations.

Source link